Advice
following a full submission:
daridorexant (Quviviq®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
SMC restriction: in patients who have failed cognitive behavioural therapy for insomnia (CBT-I) or for whom CBT-I is unsuitable or unavailable.
Daridorexant, compared with placebo, improved time to fall asleep and waking after sleep onset in adults with insomnia.
Medicine details
- Medicine name:
- daridorexant (Quviviq)
- SMC ID:
- SMC2611
- Indication:
Treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
- Pharmaceutical company
- Idorsia Pharmaceuticals UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 08 April 2024